UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 155 filers reported holding UNIQURE NV in Q2 2021. The put-call ratio across all filers is 0.17 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $86,385 | -36.5% | 12,874 | +8.4% | 0.00% | 0.0% |
| Q2 2023 | $136,110 | -44.6% | 11,877 | -2.7% | 0.00% | -50.0% |
| Q1 2023 | $245,869 | -8.6% | 12,208 | +2.9% | 0.00% | -33.3% |
| Q4 2022 | $269,025 | +25.7% | 11,867 | +4.0% | 0.00% | +50.0% |
| Q3 2022 | $214,000 | +1.9% | 11,409 | +1.2% | 0.00% | 0.0% |
| Q2 2022 | $210,000 | -30.2% | 11,272 | +19.9% | 0.00% | 0.0% |
| Q3 2021 | $301,000 | +7.9% | 9,401 | +3.6% | 0.00% | 0.0% |
| Q2 2021 | $279,000 | -14.7% | 9,071 | -6.6% | 0.00% | -33.3% |
| Q1 2021 | $327,000 | -6.3% | 9,715 | +0.5% | 0.00% | 0.0% |
| Q4 2020 | $349,000 | -5.4% | 9,667 | -3.6% | 0.00% | -25.0% |
| Q3 2020 | $369,000 | +10.8% | 10,028 | +35.8% | 0.00% | -20.0% |
| Q2 2020 | $333,000 | -14.4% | 7,384 | -9.9% | 0.01% | -28.6% |
| Q1 2020 | $389,000 | – | 8,192 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 841,471 | $15,786,000 | 5.69% |
| Nantahala Capital Management | 2,901,929 | $54,440,000 | 3.52% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 544,500 | $10,209,000 | 3.27% |
| 683 Capital Management, LLC | 1,373,600 | $25,768,000 | 1.99% |
| PFM Health Sciences, LP | 2,393,311 | $44,899,000 | 1.62% |
| Integral Health Asset Management, LLC | 433,000 | $8,123,000 | 1.58% |
| Privium Fund Management B.V. | 238,998 | $4,283,000 | 1.56% |
| Nantahala Capital Management | 1,000,000 | $18,760,000 | 1.21% |
| Henry James International Management Inc. | 89,469 | $1,678,000 | 0.94% |
| Altium Capital Management LP | 105,000 | $1,970,000 | 0.72% |